Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis
antigen (CTA) gene family, plays a pivotal role in multiple cellular processes and …

Around 15 years ago, imatinib mesylate (Gleevec® or Glivec®, Novartis, Switzerland)
became the very first'targeted'anticancer drug to be clinically approved. This drug constitutes …

The successful immunotherapy of acute myeloid leukemia (AML) has been hampered
because most potential antigenic targets are shared with normal hematopoietic stem cells …

The naive phenotype of cord blood (CB) T cells may reduce graft-versus-host disease after
umbilical cord blood transplantation, but this naivety and their low absolute numbers also …

Preferentially expressed antigen in melanoma (PRAME) is a cancer-testis antigen that is
expressed in many cancers and leukemias. In healthy tissue, PRAME expression is limited …

Purpose: In human leukocyte antigen (HLA)–matched stem cell transplantation (SCT), it has
been shown that beneficial immune response mediating graft-versus-tumor (GVT) …

Allogeneic haematological stem cell transplantation (HSCT) has developed into
immunotherapy. Donor CD4+, CD8+ and natural killer (NK) cells have been reported to …

Medulloblastoma is the most frequent malignant childhood brain tumor with a high morbidity.
Identification of new therapeutic targets would be instrumental in improving patient …

Cancer‐testis antigens (CTA) represent attractive targets for tumor immunotherapy.
However, a broad picture of CTA expression in acute myeloid leukemia (AML) is missing …

Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell
transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the …